Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.

Details

Ressource 1Download: BIB_A5C4E2B35318.P001.pdf (589.91 [Ko])
State: Public
Version: Author's accepted manuscript
Serval ID
serval:BIB_A5C4E2B35318
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.
Journal
Plos One
Author(s)
Carmeli C., Knyazeva M.G., Cuénod M., Do K.Q.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
7
Number
2
Pages
e29341
Language
english
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Abstract
Glutathione (GSH) dysregulation at the gene, protein, and functional levels has been observed in schizophrenia patients. Together with disease-like anomalies in GSH deficit experimental models, it suggests that such redox dysregulation can play a critical role in altering neural connectivity and synchronization, and thus possibly causing schizophrenia symptoms. To determine whether increased GSH levels would modulate EEG synchronization, N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients in a randomized, double-blind, crossover protocol for 60 days, followed by placebo for another 60 days (or vice versa). We analyzed whole-head topography of the multivariate phase synchronization (MPS) for 128-channel resting-state EEGs that were recorded at the onset, at the point of crossover, and at the end of the protocol. In this proof of concept study, the treatment with NAC significantly increased MPS compared to placebo over the left parieto-temporal, the right temporal, and the bilateral prefrontal regions. These changes were robust both at the group and at the individual level. Although MPS increase was observed in the absence of clinical improvement at a group level, it correlated with individual change estimated by Liddle's disorganization scale. Therefore, significant changes in EEG synchronization induced by NAC administration may precede clinically detectable improvement, highlighting its possible utility as a biomarker of treatment efficacy. TRIAL REGISTRATION: ClinicalTrials.gov NCT01506765.
Keywords
Acetylcysteine/pharmacology, Adult, Biological Markers, Cross-Over Studies, Double-Blind Method, Electroencephalography/methods, Female, Free Radical Scavengers/pharmacology, Glutathione/metabolism, Humans, Male, Models, Statistical, Multivariate Analysis, Oscillometry, Oxidation-Reduction, Placebos, Schizophrenia/drug therapy, Schizophrenia/physiopathology, Signal Processing, Computer-Assisted
Pubmed
Web of science
Open Access
Yes
Create date
06/03/2012 14:43
Last modification date
20/08/2019 15:10
Usage data